Ana Sayfa İkonu
Liv Doctors
Prof. MD. H. Levent Doğanay
Prof. MD. H. Levent Doğanay
Prof. MD.

H. Levent Doğanay

Liv Hospital Ulus
Gastroenterology
Hospital
Choose Department
Before Noon
Afternoon
You must select a hospital to make an appointment.
You can call our Call Center at 444 4 548 for available appointment slots and information.
Areas of Interests
  • Endoscopy
  • Colonoscopy
  • Bile Duct Obstructions (ERCP- Cholangioscopy)
  • Advanced Endoscopic Procedures (EMR, ESD)
  • Liver Diseases
  • Chronic Viral Hepatitis
  • Fatty Liver Disease
  • Cancer
  • Liver Elastography (Fibroscan)
  • Endoscopic obesity treatments (Gastric Balloon, Endoscopic Sleeve Gastrectomy)
Education
  • 1995–2001: Aegean University Faculty of Medicine– Medical Doctor
  • 2002–2006: Dokuz Eylul University – Interior Diseases Specialist Training
  • 2008–2011: Göztepe Training and Research Hospital – Gastroenterology Minor Specialization Training
Professional and Academic Experience
  • 2022–2026: VM Pendik Medical Park Hospital – Professor of Gastroenterology
  • 2022–Present: Bahçehir University Faculty of Medicine– Interior Professor of Diseases and Gastroenterology
  • 2021–2022: Ümraniye Training and Research Hospital – Professor of Gastroenterology
  • 2024–Present: Hepato Gastroenterology Association (Hebipa) – Member of the Board of Directors
  • 2021–2023: Turkish Liver Research Association (TKAD) – Member of the Board of Directors
  • 2015–2021: Ümraniye Training and Research Hospital – Gastroenterology Clinic Education and Administrative Officer
  • 2014–2022: Ümraniye Training and Research Hospital – Gastroenterology Associate Professor
  • 2011–2014: Ümraniye Training and Research Hospital – Gastroenterology Associate Professor
  • 2015–2022: Istanbul Provincial Health Directorateü – Genomic Laboratory (GLAB) Coordinatorö
  • 2014–2021: Northern Clinics of Istanbul Journal (indexed in WoS and PubMed) – Founding Editor
  • 2008–2011: Göztepe Training and Research Hospital – Gastroenterology Subspecialty Assistant
  • 2007–2007: Nusaybin State Hospital – Interior Diseases Specialist
  • 2002–2006: Dokuz Eylul University Faculty of Medicine– Interior Diseases Assistant
Academic Studies
  • Can ND, Akcay IM, Celik E, Ciftci C, Unal B, Agaoglu NB, Doganay HL, Dinler Doganay G. Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients. Human Genomics. 2026;20(1):39. https://doi.org/10.1186/s40246-026-00915-0
  • Bueno Álvez M, Bergström S, Kenrick J, Johansson E, Åberg M, et al. (including Doğanay L). A human pan-disease blood atlas of the circulating proteome. Science. 2025;390(6779):eadx2678. https://doi.org/10.1126/science.adx2678
  • Agaoglu NB, Unal B, Hayes CP, Walker M, Ng OH, Doganay L, Can ND, Rana HQ, Ghazani AA. Genomic disparity impacts variant classification of cancer susceptibility genes in Turkish breast cancer patients. Cancer Medicine. 2024;13(3):e6852. https://doi.org/10.1002/cam4.6852
  • Li X, Yang H, Jin H, Turkez H, Ozturk G, Doganay HL, Zhang C, Nielsen J, Uhlén M, Borén J, Mardinoglu A. The acute effect of different NAD+ precursors included in the combined metabolic activators. Free Radical Biology and Medicine. 2023;205:77–89. https://doi.org/10.1016/j.freeradbiomed.2023.05.032
  • Yang H, Li X, Jin H, Turkez H, Ozturk G, Doganay HL, Zhang C, Nielsen J, Uhlén M, Borén J, Mardinoglu A. Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators. Free Radical Biology and Medicine. 2023;204:347–358. https://doi.org/10.1016/j.freeradbiomed.2023.05.013
  • Yilmaz Y, Zeybel M, Adali G, et al. (including Doganay L). TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease. Hepatology Forum. 2023;4(Suppl 1):1–32. https://doi.org/10.14744/hf.2023.2023.0011
  • Bulur A, Özdil K, Bilgiç NM, Kürbüz K, Öztürk O, Çalışkan Z, Sayar S, Atalay R, Doğanay HL. Bilateral subcapsular cataract in a patient with Crohn's disease taking oral budesonide therapy: A case report. Journal of European Internal Medicine Professionals. 2023;1(4):167–169. https://doi.org/10.5281/zenodo.10019776
  • Dincer MT, Eren N, Murt A, Yildiz N, Özcan ŞG, Ergül M, et al. (including Doğanay HL). A comparison of antibody response in kidney transplant recipients and healthcare workers who had PCR-confirmed COVID-19 infection. Turkish Journal of Medical Sciences. 2022;52(6):1754–1761. https://doi.org/10.55730/1300-0144.5520
  • Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, Kanatsiz E, Kiyak M, Ozdil K, Doganay HL. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients on treatment. World Journal of Gastroenterology. 2022;28(6):665–674. https://doi.org/10.3748/wjg.v28.i6.665
  • Agaoglu NB, Yildiz J, Akgun Dogan O, Kose B, Alkurt G, Kendir Demirkol Y, Irvem A, Doganay L, Dinler Doganay G. COVID-19 PCR test performance on samples stored at ambient temperature. Journal of Virological Methods. 2022;301:114404. https://doi.org/10.1016/j.jviromet.2021.114404
  • Temiz MZ, Hacibey I, Yazar RO, Sevdi MS, Kucuk SH, Alkurt G, Doganay L, Dinler Doganay G, Dincer MM, Yuruk E, Erkalp K, Muslumanoglu AY. Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: A prospective pilot study. Renal Failure. 2022;44(1):233–240. https://doi.org/10.1080/0886022X.2022.2032743
  • Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, Kose S, Akhan S, Akalin EH, Sezer Z, Ozdarendeli A, Unal S; TURKOVAC Study Group. Efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac in healthy subjects: A randomized, observer-blinded, non-inferiority phase III trial. Vaccines (Basel). 2022;10(11):1865. https://doi.org/10.3390/vaccines10111865
  • Agaoglu NB, Ng OH, Unal B, Dogan OA, Amanvermez U, Yildiz J, Doganay L, Ghazani AA, Rana HQ. Concurrent pathogenic variants of BRCA1, MUTYH and CHEK2 in a hereditary cancer family. Cancer Genetics. 2022;268–269:128–136. https://doi.org/10.1016/j.cancergen.2022.10.144
  • Guzelbulut F, Karaogullarindan U, Akkiz H, et al. (including Doganay HL). Characteristics of patients with hepatocellular carcinoma: A multicenter study. Hepatology Forum. 2022;3(3):71–76. https://doi.org/10.14744/hf.2022.2022.0028
  • Atalay R, Sayar S, Ayrancı FG, Çakmak Ş, Tanboğa İH, Doğanay L, Özdil K. Does hepatic steatosis influence the virological response with chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate? Turkish Journal of Gastroenterology. 2022;33(7):587–595. https://doi.org/10.5152/tjg.2022.21051
  • Çalım-Gürbüz B, Güvendir İ, Ünal B, Erdoğan-Durmuş Ş, Topal CS, Ağaoğlu NB, Doğanay HL, Kızılboğa T, Zemheri IE. Immunohistochemical evaluation of BAP1 expression in breast cancer with known BRCA1 and BRCA2 mutations and comparison with histopathological features. International Journal of Surgical Pathology. 2022;30(4):397–404. https://doi.org/10.1177/10668969221085969
  • Erdem L, Akbal E, Koçak E, et al. (including Doğanay L). A new risk-scoring system for colorectal cancer and polyp screening by Turkish Colorectal Cancer and Polyp Study Group. Turkish Journal of Gastroenterology. 2022;33(4):286–293. https://doi.org/10.5152/tjg.2022.21072
  • Agaoglu NB, Unal B, Akgun Dogan O, Kanev MO, Zolfagharian P, Ozemri Sag S, Temel SG, Doganay L. Consistency of variant interpretations among bioinformaticians and clinical geneticists in hereditary cancer panels. European Journal of Human Genetics. 2022;30(3):378–383. https://doi.org/10.1038/s41431-022-01060-7
  • Agaoglu NB, Unal B, Akgun Dogan O, Zolfagharian P, Sharifli P, Karakurt A, Can Senay B, Kizilboga T, Yildiz J, Dinler Doganay G, Doganay L. Determining the accuracy of next generation sequencing based copy number variation analysis in hereditary breast and ovarian cancer. Expert Review of Molecular Diagnostics. 2022;22(2):239–246. https://doi.org/10.1080/14737159.2022.2048373
  • Akgun-Dogan O, Ağaoğlu NB, Kendir Demirkol Y, Doğanay L, Ergül Y, Karacan M. Mutational spectrum of congenital long QT syndrome in Turkey; identification of 12 novel mutations across KCNQ1, KCNH2, SCN5A, KCNJ2, CACNA1C, and CALM1. Journal of Cardiovascular Electrophysiology. 2022;33(2):262–273. https://doi.org/10.1111/jce.15306
  • Kilbas PO, Can ND, Kizilboga T, Ezberci F, Doganay HL, Arisan ED, Dinler Doganay G. CRISPR/Cas9-mediated Bag-1 knockout increased mesenchymal characteristics of MCF-7 cells via Akt hyperactivation-mediated actin cytoskeleton remodeling. PLoS One. 2022;17(1):e0261062. https://doi.org/10.1371/journal.pone.0261062
  • Kahraman R, Şahin A, Öztürk O, Çalhan T, Sayar S, Kanat E, Doğanay L, Özdil K. Effects of long-term tenofovir and entecavir treatment on bone mineral density in patients with chronic hepatitis B. Turkish Journal of Gastroenterology. 2022;33(1):35–43. https://doi.org/10.5152/tjg.2020.18024
  • Gökçen P, Çakmak E, Adalı G, Doğan HO, Özer H, Öztürk O, Doğanay HL, Özdil K. Predictive value of the intestinal free fatty acid binding protein in celiac disease. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi. 2022;13(1):30–35. https://doi.org/10.31067/Acusaglik.979140
  • Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Aslan E, Özdil K, Doğanay HL. Comparison of the efficacy of entecavir and tenofovir in reducing hepatocellular carcinoma risk in chronic hepatitis B patients: A real-life study in Turkey. Turkish Journal of Gastroenterology. 2021;32(4):412–421. https://doi.org/10.5152/tjg.2021.20423
  • Zhong W, Altay O, Arif M, Edfors F, Doganay L, Mardinoglu A, Uhlén M, Fagerberg L. Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. EBioMedicine. 2021;74:103723. https://doi.org/10.1016/j.ebiom.2021.103723
  • Tabak F, Şirin G, Demir M, et al. (including Doğanay HL). Demographic characteristics and transmission risk factors of patients with hepatitis C virus in Turkey: The EPI-C, a multicenter and cross-sectional trial. Viral Hepatitis Journal. 2021;27(3):109–117. https://doi.org/10.4274/VHD.GALENOS.2021.2021-1-3
  • Bulut SSD, Sakci Z, Oysu AS, Kulali F, Avci MT, Doganay L, Irvem A, Bukte Y. Chest computed tomography findings of 1271 patients with COVID-19 pneumonia and classifications with different age groups: A descriptive study from Istanbul, Turkey. Revista da Associação Médica Brasileira. 2021;67(11):1531–1537. https://doi.org/10.1590/1806-9282.20210150
  • Tanriover MD., Doğanay L, Akova M., Güner HR, Azap A, Akhan S., Köse Ş,Erdinç FŞ, Akalın EH., Tabak EF, Pullukçu H., Batum Ö., Yavuz S., Turhan Ö., Yıldırmak MT., Köksal İ., Taşova Y., Korten V., Yılmaz G., Çelen MK., Altın S., Çelik İ., Bayındır Y., Karaoğlan İ., Yılmaz A., Özkul A., Gür H., Unal S., and the CoronaVac Study Group. Efficacy and safety of an inactivated whole virion SARS-CoV-2 vaccine, CoronaVac: interim results of a randomised, double-blind, placebo-controlled phase III clinical trial in Turkey, Lancet 2021;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X.
  • Tanriover MD., Doğanay L, Serhat Ünal, Akova M. Coronavac efficacy data from Turkey. Lancet 2021; 398(10314):1874. doi: 10.1016/S0140-6736(21)02286-8.
  • Altay O., Yang H., Aydin M., Alkurt G., Altunal N., Kim W., Akyol D., Arif M., Zhang C., Dinler-Doganay G., Turkez H., Shoaie S., Nielsen J., Boren J., Doganay L., Uhlen M., Mardinoglu A. Combined metabolic coactivators accelerates recovery in mild to-moderate COVID-19, Advanced Science. doi.org/10.1002/advs.202101222
  • Agaoglu NB, Doganay L. Concurrent pathogenic variations in patients with hereditary cancer syndromes, European Journal of Medical Genetics, 2021;64(12);104366. doi: 10.1016/j.ejmg.2021.104366.
  • Can N. D., Basturk E., Kizilboga T., Akcay I. M., Dingiloglu B., Acar S., Elibeyli E., Muratcıoglu S., Januzzi A., Gursoy A., Keskin O., Doganay H. L., Karademir-Yilmaz B., Dinler-Doganay G. Interactome analysis of Bag-1 isoforms reveals novel interaction partners in ER- associated degradation. Plos One 2021;16(8):e0256640. doi: 10.1371/journal.pone.0256640
  • Alkurt G., Ahmet M., Aydın Z., Tatlı O., Agaoglu NB., Irvem A., Aydın M., Karaali R., Günes, M., Yeşilyurt B., Türkez H., Mardinoglu A., Doganay M., Basinoglu F., Seyahi N., Dinler Doganay G., Doganay L. Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey, Plos One 2021:16(3): e0247865, [doi: 10.1371/journal.pone.0247865](https://doi.org/10.1371/journal.pone.0247865).
  • Dogan O. A., Kose B., Agaoglu N. B., Yildiz J., Alkurt G., Demirkol Y. K., Irvem A., Dinler- Doganay G., L Doganay. Does sampling saliva increase detection of SARS-CoV-2 by RT-PCR? Comparing saliva with oro-nasopharyngeal swabs. J Virologic Methods 2021(290): 114049. doi: 10.1016/j.jviromet.2020.114049.
  • Akcay IM, Celik E, Agaoglu NB, Alkurt G, Kizilboga Akgun T, Yildiz J, Enc F, Kir G, Canbek S, Kilic A, Zemheri E, Ezberci F, Ozcelik M, Dinler Doganay G, Doganay L. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls. Int J Cancer. 2021; 148(2): 285295. doi: 10.1002/ijc.33199.
  • Sayar S., Gökçen P., Aykut H., Adalı G., Doğanay HL, Özdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Med Bull Sisli Etfal Hosp 2021;55(3):412–418. doi: 10.14744/SEMB.2021.95825
  • Sözeri B, Demir F, Sönmez HE, Karadağ ŞG, Demirkol YK, Doğan ÖA, Doğanay HL, Ayaz NA. Comparison of the clinical diagnostic criteria and the results of the next generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clin Rheumatol. 2021;40(6):2327-37. doi: 10.1007/s10067-020-05492-8.
  • Bulur A, Ozdil K, Doganay L, Ozturk O, Kahraman R, Demirdag H, Caliskan Z, Mutlu Bilgic N, Kanat E, Serap Erden A, Mehmet Sokmen H. Polypoid lesions detected in the upper gastrointestinal endoscopy: A retrospective analysis in 19560 patients, a single-center study of a 5-year experience in Turkey. North Clin Istanb. 2020 Nov 27;8(2):178-185. doi: 10.14744/nci.2020.16779.
  • Sozeri B, Ercan G, Dogan OA, Yıldız J, Demir F, Doğanay L. The same mutation in a family with adenosine deaminase 2 deficiency. Rheumatol Int. 2021;41(1). doi: 10.1007/s00296-019-04444-z.
  • Geyik G, Sahin A, Pekcioglu Y, Okuroglu N, Doganay L, Ozdil K. Is NRS-2002 a reliable tool in the nutritional assessment of cirrhosis: A comparative study. Acta Medica Mediterranea. 2021;37(1):43–50.
  • Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Ozdil K., Doganay L. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. Journal of Viral Hepatitis. 2021;28(5).
  • Gokcen P, Cakmak E, Adali G, Dogan HO, Yildiz SN, Ozturk O, Doganay L, Ozdil K. Liver Fatty Acid Binding Protein: Is it an early diagnostic and prognostic marker in liver damage? Medical Science and Discovery. 2021;8(4).
  • Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, Melidou A, Neher RA, O'Toole Á, Pereyaslov D; WHO European Region sequencing laboratories and GISAID EpiCoV group\. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Euro Surveill. 2020 Aug;25(32):2001410. doi: 10.2807/1560-7917.ES.2020.25.32.2001410.
  • Doganay L, Agaoglu NB, Irvem A, Alkurt G, Yildiz J, Kose B, Demirkol YK, Dogan OA, Doganay GD. Responding to COVID-19 in Istanbul: Perspective from genomic laboratory. North Clin Istanb. 2020;7(3):311-312. doi: 10.14744/nci.2020.30075.
  • Karacan I, Akgun TK, Agaoglu NB, Irvem A, Alkurt G, Yildiz J, Kose B, Ozel AS, Altunal LN, Can ND, Demirkol YK, Aydin M, Dogan OA, Doganay L, Doganay GD. The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey. North Clin Istanb. 2020;7(3):203-209. doi: 10.14744/nci.2020.90532.
  • Temiz MZ, Dincer MM, Hacibey I, Yazar RO, Celik C, Kucuk SH, Alkurt G, Doganay L, Yuruk E, Muslumanoglu AY. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: A cross-sectional, pilot study. Andrologia. 2020(26): e13912. doi: 10.1111/and.13912.
  • Sayar S, Ayranci G, Kürbüz K, Ak Ç, Tarikçi Kiliç E, Kahraman R, Atalay R, Öztürk O, Çalişkan Z, Adali G, Doganay L, Özdil K. High frequency of gastric cancer precursor lesions in patients with gastric xanthelasma: a prospective case-control study. Eur J Gastroenterol Hepatol. 2020;32(9):1130-1134. doi:10.1097/MEG.0000000000001795.
  • Demir F, Bolac GL, Merter T, Canbek S, Dogan OA, Demirkol YK, Yildiz J, Doganay HL, Sozeri B. The musculoskeletal system manifestations in children with familial Mediterranean fever. North Clin Istanb. 2020 4;7(5):438-442. doi: 10.14744/nci.2020.96636.
  • Sayar S, Kürbüz K, Kahraman R, Öztürk O, Çalışkan Z, Doğanay HL, Özdil K. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. Turk J Gastroenterol. 2020;31(7):522-528. doi: 10.5152/tjg.2020.19295.
  • Demir F, Doğan ÖA, Demirkol YK, Tekkuş KE, Canbek S, Karadağ ŞG, Sönmez HE, Ayaz NA, Doğanay HL, Sözeri B. Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clin Rheumatol. 2020;39(12):3733-3745. doi: 10.1007/s10067-020-05108-1.
  • Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2019:25;7(1):49-55. doi: 10.14744/nci.2018.78800.
  • Sayar S, Atalay R, Çakmak Ş, Ayrancı G, Kürbüz K, Kahraman R, Caliskan Z., Ozturk O., Demirdağ H., Adali G., Ozdil K., Doganay L. Diagnostic Performance of Non-invasive Fibrosis Indexes in Hepatitis B Related Fibrosis. Viral Hepatitis Journal. 2020;26(2).
  • Değertekin B, Demir M, Akarca US, Kani HT, Üçbilek E, Yıldırım E, Güzelbulut F, Balkan A, Vatansever S, Danış N, Demircan M, Soylu A, Yaras S, Kartal A, Kefeli A, Gündüz F, Yalçın K, Erarslan E, Aladağ M, Harputluoğlu M, Özakyol A, Temel T, Akarsu M, Sümer H, Akın M, Albayrak B, Sen İ, Alkım H, Uyanıkoğlu A, Irak K, Öztaşkın S, Uğurlu ÇB, Güneş Ş, Gürel S, Nuriyev K, İnci İ, Kaçar S, Dinçer D, Doğanay L, Göktürk HS, Mert A, Coşar AM, Dursun H, Atalay R, Akbulut S, Balkan Y, Koklu H, Şimşek H, Özdoğan O, Çoban M. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Turk J Gastroenterol. 2020 Dec;31(12):883-893. doi: 10.5152/tjg.2020.20696.
  • Çalışkan Z, Demircioglu K, Sayar S., Kahraman R., Caklili Ö, Özcan FB, Köstek Ö,Baycan OF, Doganay L, Caliskan M. Lipid profile, atherogenic indices, and their relationship with epicardial fat thickness and carotid intima–media thickness in celiac disease. North Clin Istanb. 2019; 6(3): 242-247. doi: 10.14744/nci.2019.54936.
  • Akcay IM, Katrinli S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol. 2018;24(30):3347-3360. doi: 10.3748/wjg.v24.i30.3347.
  • Celik E, Ermis Tekkus K, Akcay IM, Alkurt Sal G, Ezberci F, Dinler Doganay G, Doganay L. Identification of a BRCA2 mutation in a Turkish family with early-onset breast cancer. Clin Case Rep. 2018;6(9):1751-1755. doi: 10.1002/ccr3.1625.
  • Kilic E, Doganay L, Ozdil K. Endoscopic retrograde cholangiopancreaticography in elderly patients: A reliable alternative in sepsis. North Clin Istanb. 2018; 5(2): 169-170. doi: 10.14744/nci.2018.92679.
  • Katrinli S, Nigdelioglu A, Ozdil K, Dinler-Doganay G, Doganay L. The association of variations in TLR genes and spontaneous immune control of hepatitis B virus. Clin Res Hepatol Gastroenterol. 2018;42(2):139-144. doi: 10.1016/j.clinre.2017.10.002.
  • Doganay L. Hepatocellular Cancer: Is Recurrence Inevitable? J Gastrointest Cancer. 2017. doi: 10.1007/s12029-017-9967-0.
  • Ozdil K, Caliskan Z, Keles N, Ozturk O, Tekin AS, Kahraman R, Doganay L, Demircioglu K, Yilmaz Y, Caliskan M. Echocardiographic epicardial fat thickness measurement: A new screening test for subclinic atherosclerosis in patients with inflammatory bowel diseases. North Clin Istanb. 2017;4(1):4-12. doi: 10.14744/nci.2017.74508.
  • Katrinli S, Gurbet-Erkut N, Ozdil K, Yilmaz-Enc F, Ozturk O, Kahraman R, Tuncer I, Dinler-Doganay G, Doganay L. HLA DPB1 15:01 Allele Predicts Spontaneus Hepatitis B Surface Antigen Seroconversion. Acta Gastro-enterologica Belgica. 2017;80(3):351.
  • Katrinli S, Ozdil K, Sahin A, Kir G, Baykal AT, Akgun E, Sarac OS, Sokmen M, DinlerDoganay G, Doganay L. Proteomic profiling of HBV infected liver biopsies with different fibrotic stages. Proteome Science 2017;15:7. doi: 10.1186/s12953-017-0114-4.
  • Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic Success with Bismuth-containing Sequential and Quadruple Regimens in Helicobacter pylori Eradication. Arab Journal of Gastroenterology, 2017. doi: 10.1016/j.ajg.2017.05.002
  • Doganay L, Ozdil K, Memisoglu K, Katrinli S, Karakoc E, Nikerel E, Doganay G. Integrating Personalized Genomics To Turkish Health Care System: A Cancer Oriented Pilot Activity of Istanbul Northern Anatolian Public Hospitals with GLAB. North Clin Istanb. 2017; 4(1):1-3. doi: 10.14744/nci.2017.38980
  • Katrinli S, Yilmaz Enc F, Ozdil K, Ozturk O, Tuncer I, Dinler Doganay G, Doganay L. Effect of HLA-DPA1 Alleles on Chronic Hepatitis B Prognosis and Treatment Response. North Clin Istanb 2016;3(3):168-174. doi: 10.14744/nci.2016.27870
  • Ozdil K., O. Ozturk, E.S. Calik, E.S. Akbas, E. Kanat, Z. Caliskan, H. Demirdag, R. Kahraman, A. Bulur, N.M. Bilgic, Doganay L., H.M. Sokmen. Relationship between size of varices and platelet count/spleen size ratio in cirrhotic patients. North Clin Istanb. 2016;3(1):46-52. doi: 10.14744/nci.2016.60362.
  • Ozturk O, Colak Y, Senates E, Yilmaz Y, Ulasoglu C, Doganay L, Ozkanli S, Oltulu YM, Coskunpinar E, Tuncer I. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol. 2015 Jul 14;21(26):8096-102. doi: 10.3748/wjg.v21.i26.8096
  • Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis. 2015 May;16(5):286-92. doi: 10.1111/1751-2980.12237.
  • Doganay L, Katrinli S, Colak Y, Senates E, Zemheri E, Ozturk O, Enc FY, Tuncer I, Doganay GD. HLA DQB1 alleles are related with nonalcoholic fatty liver disease. Mol Biol Rep. 2014;41(12):7937-43. doi: 10.1007/s11033-014-3688-2.
  • L. Doganay, A. Fejzullahu, S. Katrinli, F. Yilmaz Enc, O. Ozturk, Y. Colak, C. Ulasoglu, I. Tuncer, G. Dinler Doganay. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. World J Gastroenterol. 2014 Jul 7;20(25):8179-86. doi: 10.3748/wjg.v20.i25.8179.
  • L. Doganay, I. Tuncer, S. Katrinli, F.Y. Enc, O. Ozturk, Y. Colak, C. Ulasoglu, G. Dinler. The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs. Clinics and research in hepatology and gastroenterology. 2013 Sep;37(4):359-64. doi: 10.1016/j.clinre.2012.10.013.
  • T. Calhan, R. Kahraman, A. Sahin, E. Senates, H.L. Doganay, E. Kanat, K. Ozdil, H.M. Sokmen. Efficacy of Two Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori: A Pilot Study. Helicobacter. 2013 Oct;18(5): 378-83. doi: 10.1111/hel.12056.
  • Y. Yilmaz, O. Ozturk, Y.O. Alahdab, E. Senates, Y. Colak, H.L. Doganay, E. Coskunpinar, Y.M. Oltulu, F. Eren, O. Atug, I. Tuncer, N. Imeryuz. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and liver disease. 2013 Jan;45(1):58-62. doi: 10.1016/j.dld.2012.08.017.
  • L. Doganay, K. Ozdil, M. Sokmen. Last blood check before passing: does alcohol prevent fibrosis? The American journal of gastroenterology. 2013 Jun;108(6):1010. doi: 10.1038/ajg.2013.74.
  • Y. Colak, E. Senates, A. Yesil, Y. Yilmaz, O. Ozturk, L. Doganay, E. Coskunpinar, O.T. Kahraman, B. Mesci, C. Ulasoglu, I. Tuncer. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013 Feb;43(1):100-7. doi: 10.1007/s12020-012-9712-1.
  • Ulasoglu, B. Isbilen, L. Doganay, F. Ozen, S. Kiziltas, I. Tuncer. Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels. World journal of gastroenterology. 2013 Apr 21;19(15):2388-94. doi: 10.3748/wjg.v19.i15.2388.
  • Y. Colak, I. Tuncer, E. Senates, O. Ozturk, L. Doganay, Y. Yilmaz. Nonalcoholic fatty liver disease: a nutritional approach. Metabolic syndrome and related disorders. 2012 Jun;10(3):161-6. doi: 10.1089/met.2011.0145.
  • Y. Colak, E. Senates, E. Coskunpinar, Y.M. Oltulu, E. Zemheri, O. Ozturk, L. Doganay, B. Mesci, Y. Yilmaz, F.Y. Enc, S. Kiziltas, C. Ulasoglu, I. Tuncer. Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Disease markers. 2012;33(2):77-83. doi: 10.3233/DMA2012-0907.
  • Y. Colak, C.Y. Karabay, I. Tuncer, G. Kocabay, A. Kalayci, E. Senates, O. Ozturk, H.L. Doganay, F.Y. Enc, C. Ulasoglu, S. Kiziltas. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. European journalofgastroenterology&hepatology.2012Jun;24(6):613-8. doi:10.1097/MEG.0b013e3283513f19.
  • Y. Colak, E. Senates, O. Ozturk, H.L. Doganay, E. Coskunpinar, Y.M. Oltulu, A. Eren, O. Sahin, S. Ozkanli, F.Y. Enc, C. Ulasoglu, I. Tuncer. Association of serum lipoprotein associated phospholipase A2 level with nonalcoholic fatty liver disease. Metabolic syndrome and related disorders. 2012 Apr;10(2):103-9. doi: 10.1089/met.2011.0111.
  • Tuncer, Y. Colak, R. Yigitbasi, E. Zemheri, T. Ayaz, E. Yorulmaz, L. Doganay, O. Ozturk, G. Adali. Mesenteric inflammatory veno-occlusive disease: an unusual cause of colonic ischemia. The Turkish journal of gastroenterology. 2011 Oct;22(5):561-2. doi: 10.4318/tjg.2011.0262.
  • L. Doganay, S. Kiziltas, Y. Colak, M. Gulluoglu, I. Tuncer. Is the lymphoma risk reduced in viral hepatitis? A cirrhotic patient with triple malignancies. The American journal of gastroenterology. 2011 Sep;106(9):1719-20; author reply 20. doi: 10.1038/ajg.2011.214.
  • Y. Colak, O. Ozturk, E. Senates, I. Tuncer, E. Yorulmaz, G. Adali, L. Doganay, F.Y. Enc. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Medical science monitor. 2011 May;17(5):HY5-9. doi: 10.12659/msm.881749.
  • Tuncer, L. Doganay, O. Ozturk. Instant control of fundal variceal bleeding with a folkloric medicinal plant extract: Ankaferd Blood Stopper. Gastrointestinal Endoscopy. 2010 Apr;71(4):873-5. doi: 10.1016/j.gie.2009.08.021.
  • H.A. Bodur, E. Saygili, S. Saygili, L.H. Doganay, S. Yesil. Continuous infusion of subcutaneous compared to intravenous insulin for tight glycaemic control in medical intensive care unit patients. Anaesthesia and intensive care. 2008 Jul;36(4):520-7. doi: 10.1177/0310057X0803600421.
  • L. Doganay, P.D. Welsby. Anthrax: a disease in waiting? Postgraduate medical journal. 2006 Nov;82(973):754-6. doi: 10.1136/pgmj.2005.044487.
  • L. Doganay, B. Akinci, N. Pekel, I. Simsek, H. Akpinar. Mesalazine-induced myopericarditis in a patient with ulcerative colitis. International journal of colorectal disease. 2006 Mar;21(2):199-200. doi: 10.1007/s00384-004-0706-1.
Projects Undertaken and Participated In
  • “Kolon Ve Meme Kanserlerinde Erken Uyarı Sistemi Oluşturulması Ve Kişisel Sağlık Sistemi E-Nabız Veri Tabanına Entegrasyonu Projesi” TÜBİTAK 1003, Proje No: 318S127, 2020-2023 , Proje Yöneticisi.
  • “Biyolojik Farmasötik Ajan Üretim Teknolojileri Geliştirme Merkezi: GLAB BİYOFARMA “İstanbul Kalkınma Ajansı (İSTKA) Fizibilite Destek Programı 2020 Proje No: TR10/19/FZD, Proje Yürütücüsü. 
  • “Türkiye Genom Projesi, Bireysel ve Dönüşümsel Tıp Alanı Uygulamalı Proje İşbirliği” TÜSEB 2019, Proje Yürütücüsü. 
  • “Sars-Cov-2 Virüs Genomunun Dizilenmesi Ve Genetik Değişimlerin İncelenmesi” TÜSEB 2020, Proje No: 2020-CV-01-8686/8789, Proje Yürütücüsü.
  • “Kanser Odaklı Veri Çözümleme, Genomik Analiz, AR-GE ve Genombilim Eğitimi Yönünde Kapasite Arttırma Projesi, Kansere ÇAARE” İstanbul Kalkınma Ajansı (İSTKA) Yenilikçi ve Yaratıcı İstanbul Mali Programı 2016, YNY2016/144 Proje Yürütücüsü.
  • “Bireye Özgü Ailesel Kanser Sendromlarını Taramaya Yönelik İleri Düzey Genetik Laboratuvar Kurma Projesi: GLAB” İSTKA Yenilikçi İstanbul Mali Programı 2015, YNK 2015/0085, Proje Yürütücüsü.
  • “eHealth Innovation in Empowering the Patient / Hastayı Güçlendiren eSağlık Yenilikler” European Commission The EU Framework Programme Horizon 2020 SC1PM-12-2016 – PCP 724409, 2017-2020, Proje Danışmanı.
  • “STAMINA - Demonstration of intelligent decision support for pandemic crisis prediction and management within and across European borders / STAMINA salgın hastalıkların tahmini ve yönetimi için akıllı karar destek sistemi araç seti geliştirilmesi” European Commission The EU Framework Programme Horizon H2020-SU-SEC-2019 – REA 883441, 2021, Proje Araştırıcısı
  • “Covid-19 hastalığının böbrek dokusu üzerine ve erkek üreme sağlığı üzerine etkilerinin araştırılması” TÜSEB, 2020-CV-01-8708/8969, 2020, Proje Araştırıcısı
  • “GENFIT-Phase 3 Elafibranor/NASH RESOLVE-IT (GFT505-315-1)” Uluslararası çok merkezli non-alkolik yağlı karaciğer hastalığında karaciğer fibrozunu düzelmeye yönelik faz 3 ilaç çalışması, 2017-2021 Proje Araştırıcısı.
  • “EPI-C, Türkiye’nin Farklı Coğrafi Bölgelerinde Hastaneye Başvuran Hepatit-C Hastaları Tarafından Belirtilmiş Risk Faktörlerinin Değerlendirildiği Çok Merkezli, Gözlemsel Çalışma” 2016, Proje Araştırıcısı.
  • “A Multicenter Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subject with Moderately to Severe Active Ulcerative Colitis” faz 2 ilaç çalışması, 2019, Proje Araştırıcısı.
  • “Covid-19 tedavisi için standard tedavide kullanılan hidroksiklorokin ile paralel kofaktör destek kombinasyonunun güvenlik ve etkinliğinin değerlendiren çok merkezli, parallel gruplu randomize açık etiketli, Faz II çalışma”, 2020, Proje Araştırıcısı. 
  • “Covid-19 Tedavisi İçin Standart Bakımda Kullanılan Hidroksiklorokin Veya Favipiraravir İle Metabolik Kofaktor Destek Kombinasyonunun Güvenlilik Ve Etkililiğini Değerlendiren Çok Merkezli, Paralel Gruplu, Randomize, Çift Kör, Faz III Çalışma” 2021, Proje Araştırıcısı
  • “İnaktif SARS-CoV-2 Aşısının (Vero Cell) Etkinlik ve Güvenliliğini Değerlendirmek için Randomize, Çift Kör, Plasebo Kontrollü Faz III Klinik ÇaIışma”,2020, Proje Araştırıcısı. 
  • “COVID-19 tanısı ile hastanede yatan hastalarda En İyi Destekleyici Bakım tedavisi ile ile birlikte Acalabrutinib kullanımının karşılaştırıldığı bir faz 2 açık etiketli randomize etkililik ve güvenlilik çalışması”, 2020, Proje Araştırıcısı.
  • “Sağlıklı Gönüllülerde İki Doz İnaktif COVID-19 Aşısına (TURKOVAC) Karşı İki Doz CoronaVac (Sinovac) Aşısının Etkililiğinin, İmmünojenisitesinin ve Güvenliliğinin Değerlendirildiği, Randomize, Gözlemci Kör Faz III Klinik Çalışma”, 2021, Proje Araştırıcısı
  • Turkish Gastroenterology Association (TGD)
  • Turkish Liver Research Association (TKAD)
  • Hepato-Gastroenterology Association (Hebipa)
  • American Association for The Advancement of Science (AAAS)
  • “Investigation of liver tissue damage pathways in chronic hepatitis B: A comparative proteomic study” Turkish Gastroenterology Association, Best Oral Presentation Third Prize 2015.
  • “Liver Fibrosis Pathways in Chronic Hepatitis B: A Comparative Proteomic Study” Viral Hepatitis Combat Association Project Support Award 2014.
  • “Relationship Between Spontaneous Seroconversion and Toll-Like Receptor Gene Polymorphism in Hepatitis B Infection.” Turkish Gastroenterology Association Best Poster Second Place Award 2014.
  • “Liver Fibrosis Pathways in Chronic Hepatitis B: A Comparative Proteomic Study” Gilead Fellowship Award 2013.
  • “Investigations of the EGF and its receptor EGFR gene variants in ulcerative colitis. XV” Euroasian Congress of Gastroenterology and Surgery, Best Poster Award Paper Three Third Prize 2016.
Ask our Experts!
You can contact with our experts for your questions!